5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule membrane-permeable derivative investigated primarily for its selective inhibition of nicotinamide N-methyltransferase (NNMT). Preclinical studies indicate that blocking NNMT activity modulates cellular energy homeostasis, elevates intracellular nicotinamide adenine dinucleotide (NAD+) availability, and influences lipid metabolism in adipocyte and skeletal muscle cell lines.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule membrane-permeable derivative investigated primarily for its selective inhibition of nicotinamide N-methyltransferase (NNMT). Preclinical studies indicate that blocking NNMT activity modulates cellular energy homeostasis, elevates intracellular nicotinamide adenine dinucleotide (NAD+) availability, and influences lipid metabolism in adipocyte and skeletal muscle cell lines.
The 5-amino-1mq research peptide (chemically designated as 5-amino-1-methylquinolinium) is a synthetic, membrane-permeable quinolinium derivative that acts as a potent, selective inhibitor of the cytosolic enzyme nicotinamide N-methyltransferase (NNMT). Classified broadly within structural metabolic research compounds alongside traditional short-chain peptides and small-molecule probes, 5-Amino-1MQ has garnered significant interest in laboratory investigations evaluating cellular bioenergetics, epigenetic methylation dynamics, and adipocyte physiology.
In physiological assays, NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). By structurally interfering with this catalytic pathway, 5-Amino-1MQ prevents the irreversible degradation of nicotinamide. This enzymatic blockade permits the salvage of nicotinamide back into the NAD+ synthesis pathway, effectively altering the intracellular pool of metabolic cofactors in experimental models of metabolic dysfunction.
Chemically, 5-Amino-1MQ features a quinolinium core substituted with an amino group at the 5-position and a methyl group at the quaternary nitrogen atom. This charged structure confers distinct solubility profiles and membrane permeability characteristics essential for cell culture assays. Unlike linear amino acid chains found in conventional signaling peptides, 5-Amino-1MQ operates as a direct small-molecule enzymatic antagonist with high binding affinity for the NNMT active site.
When handling raw powder formulations in laboratory settings, researchers must account for its hygroscopic nature and specific salt form (typically iodized or chloride salts). Structural characterization via high-performance liquid chromatography (HPLC) and mass spectrometry (MS) confirms a discrete molecular weight corresponding to the ionized quinolinium species. For comprehensive compound screening, laboratories frequently cross-reference 5-Amino-1MQ against broader catalog options in our all peptides directory.
Nicotinamide N-methyltransferase (NNMT) is predominantly expressed in metabolic tissues, including white adipose tissue (WAT), liver, and skeletal muscle. Under conditions of nutrient excess or metabolic stress, NNMT expression is significantly upregulated, leading to depletion of cellular SAM and NAM pools. The primary mechanism of the 5-amino-1mq research peptide involves binding to the substrate pocket of NNMT, competitive inhibition of substrate docking, and subsequent reduction of 1-MNA synthesis.
By inhibiting NNMT, cellular models demonstrate a conservation of both SAM and nicotinamide levels. SAM retention prevents hypermethylation of histone proteins and DNA, maintaining transcriptional stability across metabolic pathways. Concurrently, preserved nicotinamide remains accessible for conversion into nicotinamide mononucleotide (NMN) via nicotinamide phosphoribosyltransferase (NAMPT), reinforcing the primary salvage pathway required for cellular energy production.
Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme driving mitochondrial electron transport, oxidative phosphorylation, and enzymatic repair processes. Preclinical literature suggests that treatment of cultured adipocytes and myocytes with 5-Amino-1MQ yields a quantifiable increase in intracellular NAD+ concentration. Because NNMT consumption of nicotinamide acts as a metabolic sink, inhibiting this enzyme redirects metabolic flux toward NAD+ generation.
Elevated NAD+ availability directly stimulates the activity of NAD+-dependent deacetylases, primarily Sirtuin-1 (SIRT1) and Sirtuin-3 (SIRT3). Activated SIRT1 promotes the deacetylation of key transcriptional coactivators, such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). In vitro assays show that PGC-1α activation upregulates the transcription of genes responsible for mitochondrial biogenesis, fatty acid oxidation, and respiratory chain subunit synthesis, as detailed across our research hub.
Rodent models of diet-induced obesity (DIO) have provided substantial data regarding the physiological impacts of NNMT inhibition. In experimental cohorts administered 5-Amino-1MQ, researchers observed marked reductions in adipocyte volume and overall fat mass accumulation without alterations in caloric intake. Histological examination of white adipose tissue from treated murine subjects revealed decreased lipid droplet size and enhanced expression of markers associated with adipocyte browning.
In vitro differentiation assays utilizing 3T3-L1 preadipocytes demonstrate that exposure to 5-Amino-1MQ reduces intracellular triglyceride accumulation during adipogenesis. Furthermore, isolated tissue assays indicate an increase in basal metabolic rate and basal oxygen consumption rate (OCR) in adipocytes treated with NNMT inhibitors, suggesting a shift toward elevated fatty acid oxidation and substrate utilization.
Beyond adipose tissue, the impact of 5-Amino-1MQ on skeletal muscle physiology remains a key focus of bioenergetic research. Muscle atrophy and metabolic decline often coincide with diminished NAD+ concentrations and reduced mitochondrial density. Preclinical rodent studies evaluating muscle injury and age-related muscle decline indicate that NNMT inhibition supports myoblast proliferation and fusion into mature myotubes.
Extracellular flux analysis of skeletal muscle cells exposed to 5-Amino-1MQ reveals enhanced spare respiratory capacity and increased ATP production rates. By maintaining elevated NAD+/NADH ratios within the mitochondrial matrix, the compound preserves complex I and complex IV activity, attenuating ROS generation and protecting cellular structures from oxidative stress in vitro.
To contextualize the metabolic activity of 5-Amino-1MQ, researchers frequently benchmark its mechanism against alternative cellular regulators. While 5-Amino-1MQ operates via direct enzymatic inhibition of NNMT to preserve NAD+, mitochondrial signalers like the MOTS-c peptide guide focus on mitochondrial-derived peptide pathways that regulate folates and AMPK activation. Similarly, direct metabolic activators such as AICAR metabolic pathways trigger AMPK directly without modifying NNMT catalytic activity.
In experimental models evaluating direct cofactor supplementation, direct exogenous molecules outlined in NAD+ precursors bypass the salvage enzyme blockade entirely by delivering substrate directly to the cell. Comparative studies suggest that combining NNMT inhibitors with salvage pathway precursors may exert synergistic effects on intracellular NAD+ pools, providing distinct research models for investigating metabolic rate modulation.
Proper reconstitution and handling protocols are vital for maintaining the analytical integrity of 5-Amino-1MQ in vitro. The compound is supplied as a lyophilized powder or crystalline solid and exhibits optimal solubility in dimethyl sulfoxide (DMSO) or high-purity laboratory solvents. Stock solutions prepared in DMSO can typically be diluted into aqueous cell culture media or physiological buffers, provided the final organic solvent concentration remains below cytotoxic thresholds for the given cell line.
Lyophilized vials should be stored at -20°C or -80°C in a desiccated environment away from direct light exposure. Reconstituted stock solutions should be aliquoted into single-use microcentrifuge tubes to prevent degradation secondary to repeated freeze-thaw cycles. Solubilized stock integrity typically persists for 30 to 60 days when stored below -20°C under inert gas headspace.
Research outcomes depend strictly on the purity and chemical consistency of reagent-grade compounds. PX1 Research mandates rigorous analytical verification for every batch of 5-Amino-1MQ. Each lot undergoes comprehensive testing in an ISO 17025 accredited laboratory utilizing high-performance liquid chromatography (HPLC) combined with mass spectrometry (MS) to confirm chemical identity and guarantee chromatographic purity exceeding 98%.
Furthermore, PX1 Research compounds are manufactured in GMP-compliant facilities within the United States. Quality assurance protocols include quantitative bacterial endotoxin testing via Chromogenic LAL assays to ensure suitability for sensitive cell culture and biochemical research. Institutional buyers evaluating bulk procurement options can access lot-specific documentation and volume specifications through our wholesale lab account portal.
When acquiring research compounds, laboratory directors must prioritize supply chain transparency, batch-to-batch consistency, and rapid fulfillment. PX1 Research maintains state-of-the-art storage facilities in California and Arizona, ensuring temperature-controlled inventory management and same-day dispatch for orders finalized Monday through Friday before cut-off times.
Every vial of 5-amino-1mq research peptide is dispatched with full lot traceability and an accessible Certificate of Analysis (COA). By choosing PX1 Research, laboratory investigators receive premium, USA-manufactured reagents formulated strictly for in vitro and preclinical experimental design.
What is the primary molecular target of the 5-Amino-1MQ research peptide?
5-Amino-1MQ is a selective small-molecule inhibitor targeting the cytosolic enzyme nicotinamide N-methyltransferase (NNMT). It blocks the methylation of nicotinamide to 1-methylnicotinamide.
How does 5-Amino-1MQ elevate intracellular NAD+ levels in preclinical models?
By inhibiting NNMT, 5-Amino-1MQ prevents the irreversible clearance of nicotinamide. This preserves the nicotinamide precursor pool, allowing the cell to recycle it into NAD+ via the salvage pathway.
Is 5-Amino-1MQ classified structurally as a peptide or a small molecule?
Chemically, 5-Amino-1MQ is a synthetic quinolinium derivative (small molecule). However, it is frequently categorized within research peptide libraries due to its operational role in cellular signaling and metabolic research.
What solvent system is recommended for reconstituting 5-Amino-1MQ for cell culture assays?
5-Amino-1MQ exhibits optimal solubility in sterile DMSO. Stock solutions in DMSO can be diluted into culture media or phosphate-buffered saline (PBS) immediately prior to experimental treatment.
What purity standards are guaranteed by PX1 Research for 5-Amino-1MQ?
PX1 Research verifies that every lot of 5-Amino-1MQ achieves ≥98% purity, confirmed via RP-HPLC and mass spectrometry by an independent ISO 17025 accredited laboratory.
How does 5-Amino-1MQ differ from direct NAD+ precursors like NMN or NR?
Direct precursors (NMN, NR) supply substrate directly to the salvage pathway, whereas 5-Amino-1MQ inhibits the enzyme (NNMT) responsible for destroying nicotinamide, effectively sealing a primary metabolic drain.
What are the recommended storage parameters for 5-Amino-1MQ?
Lyophilized powder should be stored long-term at -20°C or -80°C in a desiccated container. Liquid stock solutions prepared in DMSO should be aliquoted and kept at -20°C to minimize degradation.
Are PX1 Research compounds tested for endotoxin levels?
Yes. Every lot undergoes chromogenic LAL testing to quantify and limit bacterial endotoxins, ensuring compound safety for sensitive cellular and biochemical assays.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.